Table 1.
The experimental design with amongst others the administered activity (MBq), specific activity (MBq/kg) and tumor and bone marrow dosimetry for the [177Lu]hu11B6 therapy study with seven (A-G) groups of animals. Included are data from our previous study with the murine 11B6 antibody 18. The range of tumor volumes at therapy start are presented in table S1 in the supplementary data. Administered amount of [177Lu]hu11B6 was 20-30 µg.
| Group | n | Treatment | Administered Activity (MBq) | Specific Activity (MBq/kg) | Weight at injection (g) | Range of Administered Activity (MBq) | Range of Specific Activity (MBq/kg) | Range of Absorbed Dose to tumor** (Gy) | Range of Absorbed Dose to bone marrow** (Gy) |
|---|---|---|---|---|---|---|---|---|---|
| BALB/c-foxn1nu/foxn1nu 177Lu-hu11B6 | |||||||||
| A | 14 | 177Lu-hu11B6 | 11.0 ± 0.8 | 512 ± 85 | 22 ± 3 | 10.2 - 12.7 | 425 - 704 | 30 - 38 | 3.8 - 4.9 |
| B | 10 | 177Lu-hu11B6 | 17.1 ± 0.5 | 674± 59 | 25 ± 3 | 16.3 - 18.0 | 610 - 782 | 48 - 53 | 6.2 - 6.9 |
| C | 9 | 177Lu-hu11B6 | 41.2 ± 1.5 | 1650 ± 131 | 25 ± 2 | 39.5 - 42.3 | 1413 - 1804 | 117 - 124 | 15 - 16 |
| D | 8 | 177Lu-ns- mAb | 18.8 ± 2.2 | 802 ± 140 | 24 ± 2 | 13 - 20.5 | 550 - 950 | - | - |
| E | 12 | hu11B6 | - | - | - | - | - | - | |
| F | 13 | Vehicle | - | - | - | - | - | - | |
| NMRI-foxn1nu/foxn1nu 177Lu-hu11B6 | |||||||||
| G | 21 | 177Lu-hu11B6 | 20.9 ± 1.3 | 586 ± 54.3 | 35.8 ± 2.8 | 18.9 - 23.1 | 483 - 670 | 56 - 68 | 7.2 - 8.8 |
| NMRI-foxn1nu/foxn1nu 177Lu-m11B6*** | |||||||||
| H | 5 | 177Lu-m11B6 | 10.1 ± 1.2 | 330 ± 25 | 30.6 ± 3.0 | 7.83 - 11.5 | 301 - 372 | 23 - 34 | 3.0 - 4.0 |
| I | 6 | 177Lu-m11B6 | 19.1 ± 1.4 | 649 ± 102 | 30.8 ± 3.0 | 17.4 - 21.1 | 512 - 812 | 51 - 62 | 6.6 - 8.0 |
| J | 3 | 177Lu-m11B6 | 36.2 ± 0.7 | 1080 ± 68 | 33.7 ± 2.9 | 35.2 - 37.0 | 1000 - 1128 | 104 - 109 | 13 - 14 |